CA2661120A1 - Programme de titrage pour le bifeprunox pour le traitement de la schizophrenie et kits d'utilisation dans ce cadre - Google Patents

Programme de titrage pour le bifeprunox pour le traitement de la schizophrenie et kits d'utilisation dans ce cadre Download PDF

Info

Publication number
CA2661120A1
CA2661120A1 CA002661120A CA2661120A CA2661120A1 CA 2661120 A1 CA2661120 A1 CA 2661120A1 CA 002661120 A CA002661120 A CA 002661120A CA 2661120 A CA2661120 A CA 2661120A CA 2661120 A1 CA2661120 A1 CA 2661120A1
Authority
CA
Canada
Prior art keywords
bifeprunox
strength
titration
compound
unit dosages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002661120A
Other languages
English (en)
Inventor
Antje A. Winsemius
Pieter W. A. J. Van Den Broeck
Luigi M. Barbato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals B.V.
Antje A. Winsemius
Pieter W. A. J. Van Den Broeck
Luigi M. Barbato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals B.V., Antje A. Winsemius, Pieter W. A. J. Van Den Broeck, Luigi M. Barbato filed Critical Solvay Pharmaceuticals B.V.
Publication of CA2661120A1 publication Critical patent/CA2661120A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
CA002661120A 2006-08-31 2007-08-29 Programme de titrage pour le bifeprunox pour le traitement de la schizophrenie et kits d'utilisation dans ce cadre Abandoned CA2661120A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US84124406P 2006-08-31 2006-08-31
EP06119936 2006-08-31
EP06119936.0 2006-08-31
US60/841,244 2006-08-31
US84149506P 2006-09-01 2006-09-01
US60/841,495 2006-09-01
EP06120016 2006-09-01
EP06120016.8 2006-09-01
PCT/EP2007/058957 WO2008025780A1 (fr) 2006-08-31 2007-08-29 Programme de titrage pour le biféprunox pour le traitement de la schizophrénie et kits d'utilisation dans ce cadre

Publications (1)

Publication Number Publication Date
CA2661120A1 true CA2661120A1 (fr) 2008-03-06

Family

ID=38704953

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002661120A Abandoned CA2661120A1 (fr) 2006-08-31 2007-08-29 Programme de titrage pour le bifeprunox pour le traitement de la schizophrenie et kits d'utilisation dans ce cadre
CA002661800A Abandoned CA2661800A1 (fr) 2006-08-31 2007-08-29 Doses de bifeprunox pour le traitement de la schizophrenie

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002661800A Abandoned CA2661800A1 (fr) 2006-08-31 2007-08-29 Doses de bifeprunox pour le traitement de la schizophrenie

Country Status (10)

Country Link
EP (2) EP2059245A1 (fr)
JP (2) JP2010501626A (fr)
KR (1) KR20090063228A (fr)
AU (2) AU2007291234A1 (fr)
BR (1) BRPI0715445A2 (fr)
CA (2) CA2661120A1 (fr)
EA (1) EA200970239A1 (fr)
IL (1) IL196867A0 (fr)
NO (1) NO20091243L (fr)
WO (2) WO2008025781A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060742A1 (fr) * 2008-11-03 2010-06-03 Solvay Pharmaceuticals B.V. Combinaison de bifeprunox et d'un médicament antipsychotique à activité antagoniste du récepteur d2/5-ht2a pour le traitement des troubles du snc
WO2010070061A1 (fr) * 2008-12-19 2010-06-24 Abbott Healthcare Products B.V. Compositions, kits et méthodes d'un programme de dosage de composés de type bifeprunox
ES2639065T5 (es) 2009-06-25 2023-01-30 Alkermes Pharma Ireland Ltd Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos
WO2011023796A1 (fr) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox destiné au traitement de l'addiction
NZ730571A (en) 2012-09-19 2018-12-21 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
EP3761983A1 (fr) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Stratégie de dosage d'aripiprazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9708389B8 (pt) * 1996-03-29 2015-12-08 Duphar Int Res compostos de piperazina e piperidina, composições farmacêuticas.
CA2310950C (fr) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. Posologie de galantamine efficace qui reduit les effets secondaires
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
AR045362A1 (es) * 2003-08-18 2005-10-26 Solvay Pharm Bv Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona
US7423040B2 (en) * 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
JP2009504799A (ja) 2005-08-22 2009-02-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ピペラジンおよびピペリジン誘導体のプロドラッグとしてのｎ−オキシド

Also Published As

Publication number Publication date
EA200970239A1 (ru) 2009-08-28
JP2010501625A (ja) 2010-01-21
IL196867A0 (en) 2009-11-18
CA2661800A1 (fr) 2008-03-06
EP2059244A1 (fr) 2009-05-20
AU2007291235A1 (en) 2008-03-06
WO2008025780A1 (fr) 2008-03-06
JP2010501626A (ja) 2010-01-21
AU2007291234A1 (en) 2008-03-06
WO2008025781A1 (fr) 2008-03-06
KR20090063228A (ko) 2009-06-17
NO20091243L (no) 2009-03-25
BRPI0715445A2 (pt) 2014-05-13
EP2059245A1 (fr) 2009-05-20

Similar Documents

Publication Publication Date Title
DK2021006T3 (en) USE OF flibanserin in postmenopausal SEXLYSTFORSTYRRELSER
AU2021229240B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CA2661120A1 (fr) Programme de titrage pour le bifeprunox pour le traitement de la schizophrenie et kits d'utilisation dans ce cadre
KR20100036367A (ko) 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
WO2004054574A1 (fr) Medicament solide administre par voie orale
US20080026050A1 (en) Solid dose formulations of a thrombin receptor antagonist
AU2015213396B2 (en) Method and composition for treating Alzheimer-type dementia
US20080132520A1 (en) Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds
US3505451A (en) Compositions and methods for alleviating schizophrenia employing one of haloperidol,trifluperidol or an acid addition salt thereof and one of desipramine,imipramine and an acid addition salt thereof
JP2006509735A (ja) オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物
KR102643197B1 (ko) 화합물 iii의 새로운 의학 용도
WO2010070061A1 (fr) Compositions, kits et méthodes d'un programme de dosage de composés de type bifeprunox
TW200817390A (en) Compositions, kits and methods of a titration schedule for bifeprunox compounds
US20100022558A1 (en) Treatment of insomnia
WO2023240092A1 (fr) Formes posologiques orales contenant de l'ebselen
WO2021234430A1 (fr) Forme galénique à libération modifiée comprenant de la vildagliptine et son procédé de fabrication
NZ770365B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130829